BD said worldwide revenues for the 3 months ended June 30, 2024 rose 2.3% from the prior-year period to $4.990 billion. The company cited the impacts of the Surgical Instrumentation platform sale, foreign currency translation and Acquisitions and other as factors in the increase.

10-QQuarterly reportFiled Aug 1, 2024Period of report Jun 30, 2024Summary published (UTC) Oct 23, 2026

Key points

AI summary

BD said worldwide revenues for the 3 months ended June 30, 2024 rose 2.3% from the prior-year period to $4.990 billion. The company cited the impacts of the Surgical Instrumentation platform sale, foreign currency translation and Acquisitions and other as factors in the increase.
BD said it announced a definitive agreement on June 3, 2024 to acquire Edward Lifesciences' Critical Care product group for $4.2 billion in cash. The company said the deal is expected to close by the end of calendar year 2024. The transaction is subject to customary regulatory reviews and closing conditions.
The company said it recorded a $62 million accrual following recent developments related to the Italian government's medical device pay back legislation, which substantially relates to years before the current fiscal year. The company explained that the amount was reflected in international revenue growth in the third quarter of fiscal 2024, Q3.
BD said operating cash flow from continuing operations for the first 9 months of fiscal 2024 was $2.666 billion, and it paid cash dividends of $825 million to common shareholders in the same period. Cash and equivalents and short-term investments, including restricted cash, were $5.338 billion as of June 30, 2024.

Key figures

Quarter ended June 30, 2024

Revenue: $5.0B
Operating income: $602M
Net income: $487M
EPS: $1.68

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Third-quarter revenue for June 30, 2024 $4.990 billion

BD said worldwide revenues for the 3 months ended June 30, 2024 rose 2.3% from the prior-year period to $4.990 billion. The company cited the impacts of the Surgical Instrumentation platform sale, foreign currency translation and Acquisitions and other as factors in the increase.

Source · Based on the MD&A text of the filing

Agreement to acquire Critical Care $4.2 billion

BD said it announced a definitive agreement on June 3, 2024 to acquire Edward Lifesciences' Critical Care product group for $4.2 billion in cash. The company said the deal is expected to close by the end of calendar year 2024. The transaction is subject to customary regulatory reviews and closing conditions.

Source · Based on the MD&A text of the filing

Italian pay back-related $62 million accrual

The company said it recorded a $62 million accrual following recent developments related to the Italian government's medical device pay back legislation, which substantially relates to years before the current fiscal year. The company explained that the amount was reflected in international revenue growth in the third quarter of fiscal 2024, Q3.

Source · Based on the MD&A text of the filing

9-month operating cash flow and dividends

BD said operating cash flow from continuing operations for the first 9 months of fiscal 2024 was $2.666 billion, and it paid cash dividends of $825 million to common shareholders in the same period. Cash and equivalents and short-term investments, including restricted cash, were $5.338 billion as of June 30, 2024.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.